0 Items
Select Page

Feline Leukemia Virus

Feline leukemia virus (FeLV) is an oncogenic gammaretrovirus that infects domestic cats and some wild felids, including the wildcat, the Florida panther and European and Iberian lynxes.  Infection with FeLV is the primary cause of oncogenesis in domestic cats worldwide. However, following the implementation of test and removal schemes and the development and widespread use of vaccines, the prevalence of FeLV infection has greatly decreased in the last two decades.

Feline Leukemia Virus Background

Feline leukemia virus (FeLV) is a widespread pathogen of the domestic cat and is one of the most common infectious cat diseases in the United States, affecting 2-3% of all cats (Cornell University, 2016).

FeLV was first described in cats in 1964. It is an RNA virus in the subfamily Oncovirinae belonging to the Retroviridae family. Cats persistently infected with FeLV serve as sources of infection for other cats. The virus is shed in saliva, nasal secretions, urine, feces, and milk of infected cats. Cats at greatest risk of FeLV infection are those that may be exposed to infected cats, either via prolonged close contact or through bite wounds. Kittens are much more susceptible to FeLV infection than are adult cats, and therefore are at the greatest risk of infection if exposed. Transmission can also take place from an infected mother cat to her kittens, either before they are born or while they are nursing (Cornell University, 2016).

There are three major subgroups of FeLV: A, B and C. These subgroups were identified by viral interference assays in which prior infection of cells with one subgroup of FeLV prevents subsequent infection with murine sarcoma virus pseudotypes bearing an envelope glycoprotein of the same subgroup. FeLV-A is the most abundant subtype and is responsible for transmission of the virus between animals. Thus, vaccination against subgroup A virus is the sole requirement for inducing immunity to infection. FeLV subgroups B and C arise in subgroup A infected cats following the establishment of viraemia (Willett and Hosie, 2013).

Most frequently, an infected cat recovers and becomes immune. However, in a few cases, the virus establishes a persistent infection, which is marked by viraemia and an increased likelihood of developing severe and ultimately fatal disease, such as lymphomas and leukaemias, immune suppression and anaemia. There is no cure for the infection but two types of vaccines for FeLV are available; an adjuvanted killed virus noninfectious vaccine and a nonadjuvanted canarypox virus-vectored recombinant infectious vaccine. However, these do not offer 100% protection from the virus.


  • Feline leukemia virus factsheet. Cornell University College of Veterinary Medicine, May 2016.
  • Feline leukaemia virus factsheet. Small Animal Veterinary Surveillance Network (SAVSNET), University of Liverpool, September 2019.
  • Willett and Hosie (2013). Feline leukaemia virus: half a century since its discovery. Vet J. 195(1):16-23.

Feline Leukemia Virus Antigens

The Native Antigen Company is pleased to provide a recombinant FeLV p27 protein, manufactured in E. coli, with greater than 95% purity.

Feline Leukemia Virus Antibodies

The Native Antigen Company offers a range of FeLV p27 antibodies allowing you to pursue more detailed R&D activities, including diagnostic assay development and vaccine research.


Check out our FAQ section for answers to the most frequently asked questions about our website and company.

Why We Need Antigen and Antibody Tests for COVID-19

RT-PCR is the workhorse of viral diagnosis and has been invaluable in COVID-19 case confirmation and isolation guidance. However, while fast and sensitive, PCR suffers from some inherent drawbacks that limit it to diagnosis during the acute phase of infection. To...

Gonorrhea: What’s Currently in the Clinical Pipeline?

This article was written by our friends at Infectious Diseases Hub, a free-to-access website that aims to deliver up-to-date, essential research and information on all aspects of microbiology, virology, mycology and parasitology – from bench to bedside....

Novel Coronavirus Antigens Now Available

The Native Antigen Company is now offering recombinant S1 and S2 glycoproteins for SARS-CoV-2 (Covid-19) in response to urgent demand. These reagents are suitable for use in basic research and the development of diagnostics and vaccines.These antigens have been...

The Why and How of Protein Conjugation

In this blog, Lead Assay Development Scientist, Toni Ertl discusses the basics of protein conjugation and introduces our new range of conjugation kits for the labelling of antigens and antibodies.Detecting Proteins If you’re trying to detect or measure the presence...

Going Viral: Why We Need New Diagnostics For a Safe and Effective Dengue Vaccine

This article is taken from European Biopharmaceutical Review January 2020, pages 44-46. © Samedan Ltd.The Dengue VirusDengue is the world’s most prevalent and consequential arboviral disease. Current estimates indicate that as many as 390 million dengue infections...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

12 + 15 =

Live Customer Feedback

Join our mailing list

* indicates required